{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:59:53Z","timestamp":1787317193858,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T00:00:00Z","timestamp":1620777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T00:00:00Z","timestamp":1620777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001254","name":"Ipsen Fund","doi-asserted-by":"publisher","award":["Medical Education Goods and Services (MEGS) grant"],"award-info":[{"award-number":["Medical Education Goods and Services (MEGS) grant"]}],"id":[{"id":"10.13039\/501100001254","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>There is no consensus on quality of life (QOL) in patients with acromegaly requiring medical treatment after surgery compared with those achieving remission by surgery alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>QuaLAT is a cross-sectional study comparing QOL in surgery-only treated acromegaly patients versus those requiring medical treatment post-surgery. Patients attending clinics were identified and divided into\u2014Group 1: patients who had surgery only and were in biochemical remission, Group 2: all patients on medical treatment post-surgery, Group 3: patients from Group 2 with biochemical control. Participants were asked to fill three questionnaires; Acromegaly Quality of Life Questionnaire (ACROQOL), 36-Item Short Form Survey (SF36), and Fatigue Severity Scale (FSS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 32 patients in Group 1 and 25 in Group 2. There was no difference in QOL scores between groups 1 and 2, as measured by ACROQOL (mean difference [MD]\u2009=\u2009\u2212 2.5, 95% CI \u2212 16.6 to 11.6; p\u2009=\u20090.72), SF36v2 [Physical component score (PCS) MD\u2009=\u2009\u2212 4.9, 95% CI \u2212 10.9 to 1.2; p\u2009=\u20090.12; mental component score MD\u2009=\u2009\u2212 3.0, 95% CI \u2212 10.5 to 4.4; p\u2009=\u20090.44], or FSS (MD\u2009=\u2009\u2212 0.004, 95% CI \u2212 1.14 to 1.33; p\u2009=\u20090.1). Comparison between groups 1 and 3 however showed that PCS (and 3 subdomains) was significantly better in group 3 (MD\u2009=\u2009\u2212 8.3, 95% CI \u2212 14.8 to -1.8; p\u2009=\u20090.01). All three QOL scores were lower when compared with healthy controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Medical treatment not only achieves a QOL comparable to surgery, it may also be associated with better QOL in physical subdomains. When compared with healthy controls, QOL remains worse in treated acromegaly patients compared to controls.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11102-021-01153-4","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T15:02:41Z","timestamp":1620831761000},"page":"768-777","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Surgically treated acromegaly patients have a similar quality of life whether controlled by surgery or requiring additional medical therapy (QuaLAT Study)"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9932-0941","authenticated-orcid":false,"given":"Muhammad Fahad","family":"Arshad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwafunto","family":"Ogunleye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Debono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,12]]},"reference":[{"issue":"24","key":"1153_CR1","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1056\/NEJMra062453","volume":"355","author":"S Melmed","year":"2006","unstructured":"Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355(24):2558\u20132573","journal-title":"N Engl J Med"},{"issue":"3","key":"1153_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","volume":"72","author":"A Fernandez","year":"2010","unstructured":"Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72(3):377\u2013382","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"1153_CR3","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/0277-9536(95)00112-K","volume":"41","author":"WHO","year":"1995","unstructured":"WHO (1995) The world health organization quality of life assessment (WHOQOL): position paper from the world health organization. Soc Sci Med 41(10):1403\u20131409","journal-title":"Soc Sci Med"},{"issue":"12","key":"1153_CR4","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1210\/jc.2014-2670","volume":"99","author":"M Mercado","year":"2014","unstructured":"Mercado M et al (2014) Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab 99(12):4438\u20134446","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1153_CR5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1210\/clinem\/dgaa868","volume":"106","author":"LHA Broersen","year":"2021","unstructured":"Broersen LHA et al (2021) Improvement in symptoms and health-related quality of life in acromegaly patients: a systematic review and meta-analysis. J Clin Endocrinol Metab 106(2):577\u2013587","journal-title":"J Clin Endocrinol Metab"},{"key":"1153_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fendo.2017.00040","volume":"8","author":"VJ Geraedts","year":"2017","unstructured":"Geraedts VJ et al (2017) Predictors of quality of life in acromegaly: no consensus on biochemical parameters. Front Endocrinol (Lausanne) 8:40","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"1153_CR7","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933\u20133951","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1153_CR8","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1210\/jc.2014-2900","volume":"99","author":"AM Abu Dabrh","year":"2014","unstructured":"Abu Dabrh AM et al (2014) Surgical interventions and medical treatments in treatment-naive patients with acromegaly: systematic review and meta-analysis. J Clin Endocrinol Metab 99(11):4003\u20134014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1153_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1046\/j.1365-2265.2002.01597.x","volume":"57","author":"SM Webb","year":"2002","unstructured":"Webb SM et al (2002) Acromegaly quality of life questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin Endocrinol (Oxf) 57(2):251\u2013258","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"1153_CR10","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1210\/jc.2011-0654","volume":"96","author":"M Madsen","year":"2011","unstructured":"Madsen M et al (2011) Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients. J Clin Endocrinol Metab 96(8):2405\u20132413","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1153_CR11","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s00701-013-1809-7","volume":"155","author":"M Milian","year":"2013","unstructured":"Milian M et al (2013) Health-related quality of life and psychiatric symptoms improve effectively within a short time in patients surgically treated for pituitary tumors\u2013a longitudinal study of 106 patients. Acta Neurochir (Wien) 155(9):1637\u20131645","journal-title":"Acta Neurochir (Wien)"},{"issue":"1","key":"1153_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1507\/endocrj.EJ16-0182","volume":"64","author":"S Fujio","year":"2017","unstructured":"Fujio S et al (2017) Changes in quality of life in patients with acromegaly after surgical remission - a prospective study using SF-36 questionnaire. Endocr J 64(1):27\u201338","journal-title":"Endocr J"},{"issue":"4","key":"1153_CR13","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1210\/jc.2013-3318","volume":"99","author":"PJ Caron","year":"2014","unstructured":"Caron PJ et al (2014) Tumor shrinkage with lanreotide autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab 99(4):1282\u20131290","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1153_CR14","doi-asserted-by":"publisher","first-page":"e006898","DOI":"10.1136\/bmjopen-2014-006898","volume":"5","author":"SO Chin","year":"2015","unstructured":"Chin SO et al (2015) Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea. BMJ Open 5(6):e006898","journal-title":"BMJ Open"},{"issue":"6","key":"1153_CR15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11102-013-0533-x","volume":"17","author":"R Mangupli","year":"2014","unstructured":"Mangupli R, Camperos P, Webb SM (2014) Biochemical and quality of life responses to octreotide-LAR in acromegaly. Pituitary 17(6):495\u2013499","journal-title":"Pituitary"},{"key":"1153_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12902-016-0096-8","volume":"16","author":"MD Bronstein","year":"2016","unstructured":"Bronstein MD et al (2016) Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study. BMC Endocr Disord 16:16","journal-title":"BMC Endocr Disord"},{"issue":"11","key":"1153_CR17","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1007\/BF03345774","volume":"32","author":"E Ghigo","year":"2009","unstructured":"Ghigo E et al (2009) Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy. J Endocrinol Invest 32(11):924\u2013933","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"1153_CR18","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s11102-015-0665-2","volume":"18","author":"K Yoshida","year":"2015","unstructured":"Yoshida K et al (2015) The quality of life in acromegalic patients with biochemical remission by surgery alone is superior to that in those with pharmaceutical therapy without radiotherapy, using the newly developed Japanese version of the AcroQoL. Pituitary 18(6):876\u2013883","journal-title":"Pituitary"},{"issue":"5","key":"1153_CR19","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/j.1365-2265.2008.03441.x","volume":"70","author":"A Colao","year":"2009","unstructured":"Colao A et al (2009) Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin Endocrinol (Oxf) 70(5):757\u2013768","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"1153_CR20","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/j.1365-2265.2011.04106.x","volume":"75","author":"Z Karaca","year":"2011","unstructured":"Karaca Z et al (2011) Comparison of primary octreotide-lar and surgical treatment in newly diagnosed patients with acromegaly. Clin Endocrinol (Oxf) 75(5):678\u2013684","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"1153_CR21","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1530\/EJE-07-0697","volume":"158","author":"MP Matta","year":"2008","unstructured":"Matta MP et al (2008) Impaired quality of life of patients with acromegaly: control of GH\/IGF-I excess improves psychological subscale appearance. Eur J Endocrinol 158(3):305\u2013310","journal-title":"Eur J Endocrinol"},{"key":"1153_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1477-7525-2-13","volume":"2","author":"X Badia","year":"2004","unstructured":"Badia X et al (2004) Acromegaly quality of life questionnaire (AcroQoL). Health Qual Life Outcomes 2:13","journal-title":"Health Qual Life Outcomes"},{"key":"1153_CR23","unstructured":"RAND-Corporation. 36-Item Short Form Survey (SF-36) scoring. 04\/01\/2021]; Available from https:\/\/www.rand.org\/health-care\/surveys_tools\/mos\/36-item-short-form\/scoring.html"},{"issue":"2","key":"1153_CR24","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1530\/eje.1.02214","volume":"155","author":"SM Webb","year":"2006","unstructured":"Webb SM et al (2006) Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. Eur J Endocrinol 155(2):269\u2013277","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1153_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1136\/jech.53.1.46","volume":"53","author":"C Jenkinson","year":"1999","unstructured":"Jenkinson C et al (1999) Assessment of the SF-36 version 2 in the United Kingdom. J Epidemiol Community Health 53(1):46\u201350","journal-title":"J Epidemiol Community Health"},{"issue":"1","key":"1153_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/ene.14520","volume":"28","author":"SO Ongre","year":"2020","unstructured":"Ongre SO et al (2020) Progression of fatigue in Parkinson\u2019s disease -a nine-year follow-up. Eur J Neurol 28(1):108\u2013116","journal-title":"Eur J Neurol"},{"issue":"1","key":"1153_CR27","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12889-020-8212-0","volume":"20","author":"KH Lee","year":"2020","unstructured":"Lee KH, Xu H, Wu B (2020) Gender differences in quality of life among community-dwelling older adults in low- and middle-income countries: results from the Study on global AGEing and adult health (SAGE). BMC Public Health 20(1):114","journal-title":"BMC Public Health"},{"issue":"5","key":"1153_CR28","doi-asserted-by":"publisher","first-page":"R67","DOI":"10.1530\/EJE-19-1023","volume":"182","author":"NF Lenders","year":"2020","unstructured":"Lenders NF, McCormack AI, Ho KKY (2020) MANAGEMENT OF ENDOCRINE DISEASE: does gender matter in the management of acromegaly? Eur J Endocrinol 182(5):R67\u2013R82","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"1153_CR29","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1210\/clinem\/dgaa405","volume":"105","author":"J Dal","year":"2020","unstructured":"Dal J et al (2020) Disease control and gender predict the socioeconomic effects of acromegaly: a nationwide cohort study. J Clin Endocrinol Metab 105(9):2975\u20132982","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1153_CR30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1530\/ERC-17-0253","volume":"24","author":"P Petrossians","year":"2017","unstructured":"Petrossians P et al (2017) Acromegaly at diagnosis in 3173 patients from the liege acromegaly survey (LAS) database. Endocr Relat Cancer 24(10):505\u2013518","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"1153_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.17925\/EE.2013.09.01.32","volume":"9","author":"I Crespo","year":"2013","unstructured":"Crespo I et al (2013) Improving quality of life in patients with pituitary tumours. Eur Endocrinol 9(1):32\u201336","journal-title":"Eur Endocrinol"},{"issue":"11","key":"1153_CR32","doi-asserted-by":"publisher","first-page":"5369","DOI":"10.1210\/jc.2004-0669","volume":"89","author":"NR Biermasz","year":"2004","unstructured":"Biermasz NR et al (2004) Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab 89(11):5369\u20135376","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1153_CR33","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1530\/EJE-07-0356","volume":"157","author":"G T'Sjoen","year":"2007","unstructured":"T\u2019Sjoen G et al (2007) Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian registry on acromegaly. Eur J Endocrinol 157(4):411\u2013417","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1153_CR34","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1530\/EJE-10-1050","volume":"164","author":"S Fieffe","year":"2011","unstructured":"Fieffe S et al (2011) Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French acromegaly registry. Eur J Endocrinol 164(6):877\u2013884","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1153_CR35","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s12020-014-0166-5","volume":"47","author":"P Anagnostis","year":"2014","unstructured":"Anagnostis P et al (2014) Psychological profile and quality of life in patients with acromegaly in Greece. Is there any difference with other chronic diseases? Endocrine 47(2):564\u2013571","journal-title":"Endocrine"},{"issue":"6","key":"1153_CR36","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1017\/cjn.2014.106","volume":"41","author":"H Fathalla","year":"2014","unstructured":"Fathalla H et al (2014) Endoscopic transphenoidal surgery for acromegaly improves quality of life. Can J Neurol Sci 41(6):735\u2013741","journal-title":"Can J Neurol Sci"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-021-01153-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-021-01153-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-021-01153-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T19:54:39Z","timestamp":1630698879000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-021-01153-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,12]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1153"],"URL":"https:\/\/doi.org\/10.1007\/s11102-021-01153-4","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,12]]},"assertion":[{"value":"4 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None relevant to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Yorkshire and the Humber Research Ethics Committee (REC reference 19\/YH\/0373).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Yes.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Yes.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}